1
|
Wallimann M, Bouayed K, Cannizzaro E, Kaiser D, Belot A, Merlin E, Poignant S, Wouters C, Hofer F, Saurenmann T, Koryllou A, Carlomagno R, Mejbri M, Hofer M, Theodoropoulou K. Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort. Pediatr Rheumatol Online J 2023; 21:96. [PMID: 37679749 PMCID: PMC10485973 DOI: 10.1186/s12969-023-00886-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/29/2023] [Accepted: 08/31/2023] [Indexed: 09/09/2023] Open
Abstract
BACKGROUND Systemic juvenile idiopathic arthritis (systemic JIA) is a severe disease with both systemic and joint inflammation. This study aims to identify predictors of disease evolution within the systemic JIA population enrolled in the Juvenile Inflammatory Rheumatism cohort (JIRcohort). METHODS Observational patient cohort study with 201 recruited children from 4 countries (3 European, 1 North Africa) from 2005 until 2019, using retrospectively (2005-2015) and prospectively (2015-2019) routine care collected data. RESULTS Sixty-five patients with complete follow-up data for 24 months after first diagnosis were classified as monophasic (n = 23), polyphasic (n = 6) or persistent group (n = 36) corresponding to their evolution (unique flare, recurrent flares, or persistent disease activity respectively). The patients of the persistent group were more likely to have an earlier disease onset, before the age of 6 (OR 2.57, 95%-CI 0.70-9.46), persistence of arthritis at 12-months post-diagnosis (OR 4.45, 95%-CI 0.58-34.20) and higher use of synthetic DMARD (sDMARD, OR 5.28, 95%-CI 1.39-20.01). Other variables like global assessment by physician and by patient and C Reactive Protein levels at 12-months post-diagnosis were assessed but without any predictive value after adjusting for confounding factors. CONCLUSIONS Our results suggest that the earlier disease onset, the persistence of arthritis throughout the first year of disease evolution and the need of sDMARD might predict a persistent disease course.
Collapse
Affiliation(s)
- M Wallimann
- Department of Woman, Mother, Child, Unit of Pediatric Immunology, Allergology and Rheumatology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - K Bouayed
- Department of Pediatrics, Unit of Rheumatology and Nephrology, Mother and Child University Hospital A. Harouchi, CHU Ibn Rochd, Casablanca, Morocco
- Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco
| | - E Cannizzaro
- Department of Pediatrics, Unit of Pediatric Rheumatology, University Children's Hospital, Zurich, Switzerland
| | - D Kaiser
- Department of Pediatrics, Unit of Pediatric Rheumatology, Childrens Hospital Lucerne, Lucerne, Switzerland
| | - A Belot
- Department of Pediatrics, Unit of Pediatric Nephrology, Rheumatology, Dermatology, Hospital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France
| | - E Merlin
- Department of Pediatrics, Clermont-Ferrand University Hospital, Clermont-Ferrand, F-63000, France
| | - S Poignant
- Department of Pediatrics, University Hospital of Nantes, Nantes, France
| | - C Wouters
- Department of Pediatrics, Unit of Pediatric Rheumatology, University Hospital Leuven, Louvain, Belgium
| | - F Hofer
- Fondation Rhumatismes-Enfants-Suisse, Etoy, 1163, Switzerland
| | - T Saurenmann
- Department of Pediatrics, Cantonal Hospital Winterthur, Winterthur, Switzerland
| | - A Koryllou
- Department of Woman, Mother, Child, Unit of Pediatric Immunology, Allergology and Rheumatology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - R Carlomagno
- Department of Woman, Mother, Child, Unit of Pediatric Immunology, Allergology and Rheumatology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - M Mejbri
- Department of Woman, Mother, Child, Unit of Pediatric Immunology, Allergology and Rheumatology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - M Hofer
- Department of Woman, Mother, Child, Unit of Pediatric Immunology, Allergology and Rheumatology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
| | - K Theodoropoulou
- Department of Woman, Mother, Child, Unit of Pediatric Immunology, Allergology and Rheumatology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
| |
Collapse
|
2
|
Papadodima O, Moulos P, Koryllou A, Piroti G, Kolisis F, Chatziioannou A, Pletsa V. Modulation of Pathways Underlying Distinct Cell Death Mechanisms in Two Human Lung Cancer Cell Lines in Response to SN1 Methylating Agents Treatment. PLoS One 2016; 11:e0160248. [PMID: 27467507 PMCID: PMC4965087 DOI: 10.1371/journal.pone.0160248] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2015] [Accepted: 07/15/2016] [Indexed: 12/13/2022] Open
Affiliation(s)
- Olga Papadodima
- Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 11635 Athens, Greece
| | - Panagiotis Moulos
- Institute of Molecular Biology and Genetics, Biomedical Sciences Research Centre ‘Alexander Fleming’, 16672 Vari, Greece
| | - Aggeliki Koryllou
- Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 11635 Athens, Greece
| | - Georgia Piroti
- Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 11635 Athens, Greece
| | - Fragiskos Kolisis
- Laboratory of Biotechnology, School of Chemical Engineering, National Technical University of Athens, 15780 Athens, Greece
| | - Aristotelis Chatziioannou
- Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 11635 Athens, Greece
- Enios Applications Private Company, 25 Al.Pantou str., 17671 Athens, Greece
- * E-mail: (AC); (VP)
| | - Vasiliki Pletsa
- Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 11635 Athens, Greece
- * E-mail: (AC); (VP)
| |
Collapse
|
3
|
Koryllou A, Patrinou-Georgoula M, Dimozi A, Kyrtopoulos SA, Pletsa V. Investigation of cell death induced by N-methyl-N-nitrosourea in cell lines of human origin and implication of RNA binding protein alterations. Anticancer Res 2011; 31:4291-4299. [PMID: 22199294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Methylating agents, a widely used class of anticancer drugs, induce DNA methylation adducts, the most biologically significant being O(6)-methylguanine. The efficacy of these drugs depends on the interplay of three DNA repair systems: base excision repair (BER), methyl-directed mismatch repair (MMR) and direct damage reversal by O(6)-methylguanine-DNA methyltransferase (MGMT). An MGMT-inducible, MMR- and BER-proficient HeLa cell line was treated with different concentrations of N-methyl-N-nitrosourea (MNU), a model S(N)1 methylating agent, analogous to widely used methylating cancer chemotherapeutic drugs, under different expression levels of the repair enzyme (MGMT). MNU induced MGMT-dependent apoptotic cell death. In this particular cellular context, the induction of apoptosis was accompanied by modifications of the RNA binding protein poly(A)polymerase and significant down-regulation of the heterogeneous nuclear ribonucleoprotein (hnRNP) C1/C2. These results implicate alterations of the above mentioned RNA binding proteins in S(N)1 methylating agent-induced cell death and apoptosis, providing a possible perspective regarding their use as biomarkers of tumor resistance/sensitivity to chemotherapy.
Collapse
Affiliation(s)
- A Koryllou
- Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, Athens, Greece
| | | | | | | | | |
Collapse
|